Tirzepatide (Injection)

Overview

Compounded tirzepatide injection is a once-weekly dual GIP and GLP-1 receptor agonist. It is prescribed only when a licensed U.S. provider determines it is clinically appropriate for you, and it is prepared individually by a state-licensed U.S. compounding pharmacy in response to a patient-specific prescription.

How it works

Tirzepatide activates both the GIP and GLP-1 receptors. These receptors are involved in appetite regulation and gastric emptying, which may reduce hunger and increase the feeling of fullness after eating. Your provider will discuss what to expect in your individual situation.

Who compounds this medication

MedicLab is a telehealth platform. MedicLab does not manufacture, compound, or dispense any medication. Compounding and dispensing are performed by an independent state-licensed U.S. compounding pharmacy, which is identified by name on the medication label and on the paperwork included with your order.

At a glance

Active ingredient

Tirzepatide

Drug class

Dual GIP and GLP-1 receptor agonist

Form

Subcutaneous injection

Administration

Once weekly, self-injected as directed by your provider

Dosing

Determined by your provider, with gradual titration

FDA status

Compounded — not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality before marketing.

Prescription

Required — issued only after licensed provider review

Storage

Refrigerate 36–46°F (2–8°C); protect from light

What is included with MedicLab